Therapy News and Research

RSS

Immunotherapy replaces surgery for early-stage dMMR cancers in landmark study

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch repair-deficient (dMMR) solid tumors across multiple types. Most patients avoided surgery with durable disease control, reshaping potential cancer treatment pathways.

28 Apr 2025

Targeted drug zongertinib shows strong results for HER2-mutant lung cancer in clinical trial

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 mutations – with manageable side effects, according to results from the Phase Ia/Ib Beamion LUNG-1 trial led by researchers from The University of Texas MD Anderson Cancer Center.

28 Apr 2025

Dana-Farber experts present innovative cancer studies at the 2025 AACR Annual Meeting

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

27 Apr 2025

MD Anderson researchers present promising clinical trial results at AACR 2025

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025.

26 Apr 2025

Exploring ondansetron as potential therapy for opioid-exposed infants

As the opioid crisis continues, the number of babies born with neonatal opioid withdrawal syndrome (NOWS) – a condition that affects infants whose mothers used opioids during pregnancy – has risen 5-fold over the past 20 years.

25 Apr 2025

Intravenous therapy promotes survival of heart muscle cells after a heart attack

Researchers have developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure.

25 Apr 2025

New RNA-based diagnostics to fight against tuberculosis

In 2023, tuberculosis (TB) killed about 1.25 million people worldwide, more than any other infectious disease on Earth — even though it is curable. Months- or even years-long regimens of potent antibiotics can eradicate the Mycobacterium tuberculosis bacteria.

25 Apr 2025

Gene therapy offers hope for children born with metachromatic leukodystrophy

If administered early, gene therapy has the potential to change the medical history of children born with metachromatic leukodystrophy (MLD), a rare and lethal neurodegenerative disease of genetic origin which leads to the progressive loss of the ability to walk, talk and interact.

25 Apr 2025

Rethinking inclusive education for children with severe illnesses

The aim of inclusive education is to ensure that students with special needs participate equally in societal life and learning.

25 Apr 2025

New biomarker offers hope for early Parkinson’s diagnosis

A misfolded protein facilitates reliable diagnosis even in the early stages of Parkinson’s disease in body fluids.

25 Apr 2025

New era of medicine emerges through structural control of nanotherapeutics

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level.

25 Apr 2025

Bruker to launch Beacon Discovery™ at AACR 2025, expanding access to live single-cell functional analysis

Bruker Corporation today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.

From Bruker Cellular Analysis 25 Apr 2025

Serum hsa_circ_101555 as a promising biomarker for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking. Circular RNAs (circRNAs) are one of the promising biomarkers.

24 Apr 2025

Novel cancer immunotherapy approach could complement existing CAR-T treatments

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

24 Apr 2025

AI tools improve detection of key immune structures in melanoma

Researchers from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) have applied AI-driven processes for detecting tertiary lymphoid structures (TLS) in thousands of digital images of melanoma tumor tissue, significantly enhancing TLS identification and survival predictions for operable stage III/IV patients.

24 Apr 2025

lncRNAs shape the tumor microenvironment and drive cancer development

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, extracellular matrix (ECM), cytokines, and growth factors, all interacting to influence tumorigenesis, progression, and metastasis.

24 Apr 2025

Manipulating a master regulator prevents tumor growth in mice

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, critical role in dampening the immune system's response to cancer.

24 Apr 2025

Surgery may not be necessary for some early-stage breast cancer patients

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center.

24 Apr 2025

Prostate cancer diagnosis is not a death sentence, study says

Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022.

24 Apr 2025

Rethinking stroke prevention for patients with mild carotid narrowing

Ischemic stroke remains one of the leading causes of death and long-term disability worldwide, with narrowing of the carotid artery due to atherosclerosis contributing to up to 30% of all cases.

24 Apr 2025